People receiving the four main treatments NHS drugs for Alzheimer’s disease face losing their medication after the National Institute for Clinical Excellence (NICE) proposed their withdrawal amid concerns of cost effectiveness.In a statement overruling recommendations made in 2001, NICE last month said that prescription of the three Acetylcholinesterase inhibitors, donepezil, rivastigmine, galantamine, and one other…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2025 All rights reserved LaingBuisson 
